Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 17Stomach Neoplasms 14Rectal Neoplasms 10Pancreatic Neoplasms 7Colonic Neoplasms 6Biliary Tract Neoplasms 5Adenocarcinoma 4HER2-positive Gastric Cancer 3Esophageal Neoplasms 3Cholangiocarcinoma 3Ovarian Neoplasms 2Neoplasms 2Lymphoma, Extranodal NK-T-Cell 2Locally Advanced Gastric Cancer 2Cirrhosis, Familial, with Pulmonary Hypertension 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Spinocerebellar Degenerations 1Rectal Neoplasms Malignant 1Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Neoadjuvant Chemotherapy 1MSI-H Colorectal Cancer 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Low Rectal Adenocarcinoma 1

Interventions

irinotecan sucrosofate 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Efficacy and Safety × Oxaliplatin × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡